| Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40057343无 PMCID | 2025-Mar-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.Vaccine | PMID 39920023无 PMCID | 2025-Mar-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide for Obesity Treatment and Diabetes Prevention.N Engl J Med | PMID 39536238无 PMCID | 2025-Mar-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis.N Engl J Med | PMID 40043236无 PMCID | 2025-Mar-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Remibrutinib in Chronic Spontaneous Urticaria.N Engl J Med | PMID 40043237无 PMCID | 2025-Mar-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study).Jpn J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39690810无 PMCID | 2025-Mar-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).BMJ Open | PMID 40044198PMC11883618 | 2025-Mar-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating the effectiveness of systemic heparin during arteriovenous fistula creation by emulating a target trial.Am J Epidemiol | PMID 38825327PMC12166180 | 2025-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.Circulation | PMID 39556242PMC11875408 | 2025-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39847361PMC11880948 | 2025-Mar-04 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 无 KM 图 |
| Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical Trial.JAMA Netw Open | PMID 40085084PMC11909609 | 2025-Mar-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.Hepatology | PMID 38875119PMC11825481 | 2025-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial.Int J Radiat Oncol Biol Phys | PMID 39353477无 PMCID | 2025-Mar-01 | 0.90 | The record reports a Phase III randomized oncology trial with drug intervention, but the abstract exclusively presents acute and late toxicity results. The primary/key efficacy endpoint for this study (expected to be a time-to-event outcome like OS or DFS) is explicitly stated as not yet available ('awaited'). Therefore, it does not meet the criterion of reporting a primary or key secondary time-to-event efficacy endpoint. | 待处理 |
| Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer.Int J Radiat Oncol Biol Phys | PMID 39357788无 PMCID | 2025-Mar-01 | 0.95 | The trial is a randomized, phase III oncology study in humans with original results. However, it compares two radiation techniques (proton vs. IMRT) and does not involve a drug-containing intervention. Furthermore, the primary endpoint is a change in a patient-reported quality-of-life score (bowel health), not a time-to-event efficacy endpoint (OS, PFS, etc.) or a survival analysis with Kaplan-Meier/HR. Therefore, it does not meet the inclusion criteria. | 待处理 |
| Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial.Int J Cancer | PMID 39501485无 PMCID | 2025-Mar-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.Am J Psychiatry | PMID 39659157无 PMCID | 2025-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study.Dermatol Surg | PMID 39692332PMC11864047 | 2025-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial.JAMA Psychiatry | PMID 39693081PMC11883513 | 2025-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of virtual reality intervention on hospitalized patients with acute pain after thoracoscopic surgery: a pilot randomized clinical trial.Int J Surg | PMID 39878180PMC12372710 | 2025-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neuromodulation for Children With Hemiparesis and Perinatal Stroke: A Randomized Clinical Trial.JAMA Neurol | PMID 39899326PMC11791770 | 2025-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of a submucosal and subserosal approach in ICG-guided laparoscopic lymphadenectomy in gastric cancer patients: long-term outcomes of a phase 3 randomized clinical trial.Int J Surg | PMID 39903562PMC12372724 | 2025-Mar-01 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 已完成 |
| Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial.J Card Fail | PMID 39182825无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial.Headache | PMID 39221611PMC11884218 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial.Eur Urol | PMID 39271420无 PMCID | 2025-Mar | 0.95 | The study is a Phase III randomized trial with oncology endpoints, but the primary experimental intervention compared is radiotherapy (hypofractionated vs. conventional fractionated), not a drug. Therefore, it does not meet the drug-containing intervention criterion for inclusion. | 待处理 |
| A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVac™ vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age.Infect Dis (Lond) | PMID 39378070无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM.J Clin Pharmacol | PMID 39417209PMC11867924 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immediate effects of propofol on mood: a randomized comparison of two doses in a cohort with depression.Psychopharmacology (Berl) | PMID 39417860无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies.J Clin Pharmacol | PMID 39453735PMC11867917 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.Lancet Infect Dis | PMID 39461355无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial.Lancet Infect Dis | PMID 39461358PMC11871998 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial.Urol Oncol | PMID 39477770无 PMCID | 2025-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections.Clin Microbiol Infect | PMID 39491784无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial.Allergy | PMID 39495086PMC11891417 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy.Allergy | PMID 39520181PMC11891431 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39521433无 PMCID | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| ONS-5010 (bevacizumab-vikg) Safety and Efficacy in Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration.Ophthalmic Surg Lasers Imaging Retina | PMID 39535413无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Progression to complete retinal pigment epithelium and outer retinal atrophy (cRORA): post hoc analysis of the GATHER1 trial.Graefes Arch Clin Exp Ophthalmol | PMID 39538001PMC11953152 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial.Qual Life Res | PMID 39565556无 PMCID | 2025-Mar | 0.45 | The record describes a Phase III randomized trial for high-risk prostate cancer, but the reported outcomes (testosterone recovery and quality of life) do not meet the criterion for survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes. | 待处理 |
| Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39571127无 PMCID | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trial.Br J Anaesth | PMID 39572271PMC11867074 | 2025-Mar | 0.95 | Study is an oncology, human, randomized, phase III trial with original results. However, the primary endpoint is 'time to return to intended oncologic therapy (RIOT)', not a standard time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The intervention is intraperitoneal ropivacaine (a local anesthetic), not a systemic anti-cancer drug, so it does not meet the drug-intervention criterion. Therefore, it is excluded. | 待处理 |
| Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.Br J Haematol | PMID 39604791无 PMCID | 2025-Mar | 0.85 | This is a randomized Phase III oncology trial with a drug intervention, but the primary endpoint is quality-of-life, not a time-to-event efficacy endpoint (OS, PFS, etc.) as required. Therefore, it is excluded. | 待处理 |
| Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGE.J Allergy Clin Immunol Pract | PMID 39613097无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39631622无 PMCID | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.Neuropsychopharmacol Rep | PMID 39632341PMC11666340 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.J Clin Oncol | PMID 39647999PMC11855994 | 2025-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.J Clin Oncol | PMID 39671538PMC11869882 | 2025-Mar | 0.80 | The study is a randomized, oncology trial with a drug-like intervention, but it is explicitly a Phase II trial, and the primary endpoint is a biomarker (Ki-67) change, not a time-to-event efficacy endpoint. Therefore, it does not meet the required criteria for inclusion in the cohort. | 待处理 |
| SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial.Bone | PMID 39674388无 PMCID | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reference Ranges and Determinants of Thyroid Function and TSH Receptor Antibodies During Early Pregnancy in Nepal.Clin Endocrinol (Oxf) | PMID 39676726PMC11788947 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.J Diabetes Sci Technol | PMID 39717993PMC11669135 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of telemedicine support for intraoperative anaesthesia care on postoperative outcomes: the TECTONICS randomised clinical trial.Br J Anaesth | PMID 39753404PMC11867081 | 2025-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |